Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...

From redness to gradual loss of vision to constant irritation, here are the early warning signs of eye diseases that should not be taken lightly.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

The beginning of the new CPD cycle means it is time to prepare a new professional development plan (PDP) and sketch out areas ...

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

An announcement from Opthea Limited ( (AU:OPT) ) is now available.

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

REED CITY — It has been one year since Riemer Eye Center purchased Precision ICare in Reed City. With the growth of the ...